Pancreatic Cancer Research

ResearcherKitakyushu Municipal Medical CenterActive in the last 2 years

Kazuyoshi Nishihara

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 6 November 2026

Matched on OpenAlex author ID A5113973965. Sources: OpenAlex.

Their work

Papers
10 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
33
Papers, trials and grants by year

2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: 2 papers · 2021: 1 paper · 2022: none · 2023: 3 papers · 2024: 1 paper

Papers 10

  1. Conversion surgery for initially unresectable locally advanced pancreatic ductal adenocarcinoma after chemotherapy followed by carbon-ion radiotherapy: a case … Co-author DOI 10.1186/s13256-023-04311-3↗
  2. A Prospective Multicenter Phase II Trial of Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer with Arte… Co-author DOI 10.1245/s10434-022-12566-1↗
  3. Prognostic Impact of Preoperative Osteosarcopenia for Patients with Pancreatic Ductal Adenocarcinoma After Curative Resection. Co-author DOI 10.1245/s10434-023-13936-z↗
  4. Preoperative frailty as a predictive factor for postoperative complications in patients with pancreatic cancer. Last author DOI 10.18999/nagjms.85.3.518↗
  5. Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel Regimen for Borderline Resectable Pancreatic Cancer with Arterial Involvement: A Prospective Mult… Co-author DOI 10.29337/ijsp.142↗
  6. Long-term survival after hepatectomy for metachronous liver metastasis of pancreatic ductal adenocarcinoma: a case report. Co-author DOI 10.1186/s40792-020-00924-8↗
  7. Correction to: Long-term survival after hepatectomy for metachronous liver metastasis of pancreatic ductal adenocarcinoma: a case report. Co-author DOI 10.1186/s40792-020-01070-x↗
  8. Significance of neoadjuvant therapy for borderline resectable pancreatic cancer: a multicenter retrospective study. Co-author DOI 10.1007/s00423-019-01754-5↗
  9. Long-Term Outcomes After Pancreatectomy for Pancreatic Ductal Adenocarcinoma in Elderly Patients: Special Reference to Postoperative Adjuvant Chemotherapy. Co-author DOI 10.1007/s00268-018-4496-y↗
  10. Effect of postoperative major complications on prognosis after pancreatectomy for pancreatic cancer: a retrospective review. First author DOI 10.1007/s00595-016-1426-1↗

Closest collaborators

The 25 strongest of 33 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Toru Nakano · 5 shared papers, 2017–2024 · strength 0.68
  2. Tomohiko Shinkawa · 4 shared papers, 2018–2024 · strength 0.59
  3. Yusuke Watanabe · 4 shared papers, 2017–2024 · strength 0.48
  4. Toshiya Abe · 3 shared papers, 2020–2023 · strength 0.45
  5. Masafumi Nakamura · 3 shared papers, 2021–2023 · strength 0.45
  6. Kenjiro Date · 2 shared papers, 2023–2024 · strength 0.41
  7. So Nakamura · 2 shared papers, 2023 · strength 0.36
  8. Susumu Eguchi · 3 shared papers, 2019–2023 · strength 0.34
  9. Masafumi Inomata · 3 shared papers, 2019–2023 · strength 0.34
  10. Hirokazu Noshirο · 3 shared papers, 2019–2023 · strength 0.34
  11. Yoshihiro Miyasaka · 3 shared papers, 2019–2023 · strength 0.34
  12. Takao Ohtsuka · 3 shared papers, 2019–2023 · strength 0.34
  13. Kousei Ishigami · 2 shared papers, 2023 · strength 0.33
  14. Kohei Nakata · 2 shared papers, 2023 · strength 0.33
  15. Naoki Ikenaga · 2 shared papers, 2023 · strength 0.33
  16. Chikanori Tsutsumi · 2 shared papers, 2020 · strength 0.27
  17. Hiroaki Nagano · 2 shared papers, 2021–2023 · strength 0.27
  18. Hiroshi Kurahara · 2 shared papers, 2019–2023 · strength 0.22
  19. Hideo Baba · 2 shared papers, 2019–2023 · strength 0.22
  20. Nobuhiro Fujita · 1 shared paper, 2023 · strength 0.18
  21. Noboru Ideno · 1 shared paper, 2023 · strength 0.18
  22. Makoto Onji · 1 shared paper, 2023 · strength 0.18
  23. Koichi Naito · 1 shared paper, 2023 · strength 0.18
  24. Toru Hisaka · 1 shared paper, 2023 · strength 0.15
  25. Hideo Baba · 1 shared paper, 2021 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.